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Abstract 
Background: Increased antimicrobial resistance 
has led to increase in mortality and morbidity. 
We conducted this study to determine and compare 
antimicrobial resistance of Multi Drug Resistant 
(MDR) and Extensively Drug Resistant (XDR) 
clinical isolates of E. coli, Pseudomonas spp. & 
Klebsiella spp. against Amikacin and Imipenem in a 
tertiary care hospital. 
Methods: This descriptive cross-sectional study 
was carried out from July 2017 to July 2018 
Department of Pathology, Holy Family Hospital, 
Rawalpindi. A total of 673 clinical isolates of E. coli, 
Klebsiella spp. and Pseudomonas spp. were 
included in this study by consecutive sampling 
technique. Data was entered in SPSS and descriptive 
statistics were applied. Chi’s square test was applied 
to determine difference in effectiveness of amikacin 
and imipenem against XDR and MDR strains of 
included micro-organisms. 
Results: A total of 673 samples were included in 
this study, out of which 431 (64.0%) strains of gram-
negative XDR organisms isolated, 123 (55.9%) strains 
were of E. coli, 134 (68.4%) of Klebsiella and 174 
(67.7%) strains were of Pseudomonas. A total of 366 
(54.4%) were obtained from male and 307 (45.6%) 
from female patients. Pseudomonas (38.2%) was 
more commonly isolated as compared to E. coli 
(32.7%). 
Conclusion: Antimicrobial resistance of XDR 
isolates of E. coli, Klebsiella spp. & Pseudomonas 
spp. against Amikacin & Imipenem is high as 
compared to MDR clinical isolates. 
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Introduction 
Centre of Disease Control (USA) has emphasized that 
human race is about to enter the “post-antibiotic” era.1 
Increasing antimicrobial resistance against commonly 
used antimicrobial agents has led to an increased 
morbidity, increased mortality, increased hospital 
stays and economic loss. 
However, human causes like over-population and 
over-usage of antibiotics & microbial is resulting in 
genetic mutations and adaptations ultimately 
increasing antimicrobial resistance. Other factors 
include over-prescription, public perception & 
behavior, commercial pressures and vaccination 
reluctance.3 
In fact, it led to the joint meeting between European 
Centre for Disease Prevention and Control (ECDC) 
and the Centres for Disease Control and Prevention 
(CDC) to define standardized terminology like Multi 
Drug Resistance (MDR), Extensively Drug Resistance 
(XDR) and Pan Drug Resistance (PDR). MDR was 
defined as acquired non-susceptibility to at least one 
agent in three or more antimicrobial categories, XDR 
was defined as non-susceptibility to at least one agent 
in all but two or fewer antimicrobial categories (i.e. 
bacterial isolates remain susceptible to only one or two 
categories).4 
Development of MDR and XDR in clinical isolates of E. 
coli, Pseudomonas spp. & Klebsiella spp. Has already 
been reported by many studies. 5 
The objective of this study was to determine and 
compare antimicrobial resistance of Multi Drug 
Resistant (MDR) and Extensively Drug Resistant 
(XDR) clinical isolates of E. coli, Pseudomonas spp. & 
Klebsiella spp. against Amikacin and Imipenem in a 
tertiary care hospital. 
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Patients and Methods 
This cross-sectional study was conducted in the 
Department of Pathology, Holy Family Hospital, 
Rawalpindi. Hospital records were analysed for a 
period of 1 year from July 2017 to July 2018. A total of 
673 clinical isolates of E. coli, Klebsiella spp. and 
Pseudomonas spp. were included in this study by 
consecutive sampling technique. Clinical Isolates of 
samples, obtained from Department of Surgery, 
Department of Medicine, ICU, Department of Burns, 
Department of Gynecology and Department of 
Pediatrics were included in this study. Sites of 
isolation of micro-organisms included were; wound, 
pus, catheter tips, urine, throat swabs, sputum and 
blood. Bacterial isolates were identified and 
antimicrobial susceptibility was determined using 
hospital guidelines. Antibiotics for Gram-negative 
pathogens used were ampicillin, gentamicin, 
tobramycin, cefazolin, ceftazidime, co-trimoxazole,  
and nitrofurantoin as first line drug; amp-sulbactam, 
amox-clav, piperacillin-tazobactum, amikacin, 
cefotaxime, cefepime, ciprofloxacin, moxifloxacin, 
imipenem and meropenem as second line drugs, 
whereas, aztreonam, chloramphenicol and tetracycline 
were used as third line drugs. Bacterial isolates were 
categorized as Multi Drug Resistant (MDR) and 
Extensively Drug Resistant (EDR). 
MDR was defined as acquired non-susceptibility to at 
least one agent in three or more antimicrobial 
categories, and, XDR was defined as non-susceptibility 
to at least one agent in all but two or fewer 
antimicrobial categories (i.e. bacterial isolates remain 
susceptible to only one or two categories). 4 
Antimicrobial susceptibility of both XDR and MDR E. 
coli, Klebsiella spp. and Pseudomonas spp. was noted 
against amikacin & imipenem along with gender, site 
and department of isolation using pro-forma 
containing demographic details and microbiological 
test records. Data was entered in SPSS and descriptive 
statistics were applied. Chi’s square test was applied 
to determine difference in effectiveness of amikacin 
and imipenem against XDR and MDR strains of 
included micro-organisms. 
 
Results 
A total of 673 samples were included in this study of 
which, 280 (41.6%) were obtained from Department of 
Surgery, 197 (29.3%) from Department of Medicine, 
104 (15.5%) from ICU, 73 (10.8%) from Department of 
Burns, 11 (1.6%) from Department of Gynecology and 
8 (1.2%) from Department of Pediatrics. 
A total of 366 (54.4%) were obtained from male and 
307 (45.6%) from female patients. There were 257 
(38.2%) isolates of Pseudomonas spp., 220 (32.7%) 
isolates of E. coli and 196 (29.1%) of Klebsiella spp. 
Out of a total of 431 (64.0%) strains of gram negative 
XDR organisms isolated, 123 (55.9%) strains were of E. 
coli, 134 (68.4%) of Klebsiella and 174 (67.7%) strains 
were of Pseudomonas. Gender wise distribution of 
XDR and MDR clinical isolates has been demonstrated 
in the table below. 
Table I: Distribution of XDR & MDR Clinical 
Isolates according to gender 
A total of 241 (35.8%) clinical isolates were 
obtained from wounds, 154 (22.9%) from pus, 94 
(14.0%) from catheter tips, 80 (11.9%) from urine 
samples, 64 (9.5%) from throat swabs, 25 (3.7%) 
from sputum cultures and 15 (2.2%) from blood. 
Site wise distribution of isolated XDR and MDR 
organisms has been demonstrated in the table 
below. 
Table II: Distribution of XDR & MDR clinical 
isolates according to site  
 
Chi’s Square Test was applied to determine 
significance of difference between antimicrobial 
susceptibility of XDR and MDR E. coli, Klebsiella spp. 
and Pseudomonas spp. against Amikacin and 
Imipenem. The difference was highly statistically 
significant (p<0.05).  
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Table III: Significance of difference between 
antimicrobial susceptibility of XDR and MDR E. 
coli, Klebsiella spp. and Pseudomonas spp. against 
Amikacin and Imipenem 
 
Discussion 
Silpi et al. reported that E. coli (35%) was the most 
commonly isolated gram-negative organism in 
department of microbiology of a tertiary care hospital 
in India followed by Pseudomonas (28.4%) while 
according to our findings, Pseudomonas (38.2%) was 
more commonly isolated as compared to E. coli 
(32.7%). It was also stated that 27.8% of Klebsiella and 
32.2% strains of Pseudomonas were XDR while 
according to our study it was: 68.4% and 67.7% 
respectively. However, the difference may be 
attributed to the time difference of 2 years between the 
aforementioned studies.5 
However, in another study conducted in India in 2018, 
it was observed that 41.3% strains of gram-negative 
bacteria were XDR in contrast to 64.0% strains in our 
study.6 
In China, antimicrobial resistance of XDR Klebsiella 
spp. against amikacin and imipenem was reported to 
be 94.3% and 100% respectively while according to our 
study, it was 59.7% and 34.3% respectively.7 
In another study conducted in China, it was observed 
that 73.9% isolates of Klebsiella were carbapenem 
resistant. Antimicrobial resistance of Klebsiella spp 
and E. coli against Amikacin was reported to be 41.8% 
and 24.1% respectively.8 
Kumar et al. reported that antimicrobial resistance of 
Pseudomonas spp. against amikacin and imipenem 
was 80% and 78% respectively, while according to our 
results, it was 78.7% and 62.6% respectively.9 
Moreover, in another study from USA, the 
antimicrobial resistance of MDR isolates of 
Pseudomonas against amikacin and imipenem has 
been reported to be 13% and 89% respectively, in 
contrast to 37.3% and 15.7% respectively observed in 
our study.10 
Another study reported the antimicrobial resistance of 
MDR Pseudomonas, Klebsiella and E. coli against 
amikacin to be 89%, 76% and 71% respectively, in 
contrast to 37.3%, 14.5% and 9.3% observed in our 
study. In the same study antimicrobial resistance of 
MDR Pseudomonas, Klebsiella and E. coli against 
imipenem was reported to be 82%, 69% and 14% 
respectively, in contrast to 15.7%, 6.5% and 9.3% 
observed in our study.11 
In a study conducted in Pakistan, antimicrobial 
resistance of MDR Pseudomonas, Klebsiella and E. coli 
against amikacin was stated to be 50.3%, 38.6% and 
10.5% respectively while that for imipenem was 15.4%, 
79.0% and 5.5% respectively.  These findings are 
comparable to our study. Slight differences may be 
attributed to a difference in setting and time 
duration.12 
Therefore, the resistance of MDR and XDR strains of 
Pseudomonas, Klebsiella and E. coli against amikacin 
and imipenem is surprisingly high. However, 
monotherapy using polymyxin B and combination 
therapy of polymyxin B with rifampin, carbapenems 
or tigecycline has been reported to effectively treat 
infections of MDR and XDR strains of gram-negative 
bacteria and also efficiently reduce hospital 
mortality.13 
However, as per our knowledge, no study has yet 
compared the efficacy of Amikacin & Imipenem 
against XDR & MDR clinical isolates of E. coli, 
Klebsiella spp. & Pseudomonas spp. 
 
Conclusion 
Antimicrobial resistance of XDR isolates of E. coli, 
Klebsiella spp. & Pseudomonas spp. against Amikacin 
& Imipenem is surprisingly high as compared to MDR 
clinical isolates. 
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